Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)

Competitors to Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)

AveXis, a Novartis Gene Therapies Company

AveXis, now part of Novartis, is a key player in the gene therapy field and focuses on spinal muscular atrophy (SMA). Their leading therapy, Zolgensma, showcases their strength in AAV-based therapies, which directly competes with Rocket's offerings. With Novartis's extensive resources and global reach, AveXis may have an advantage in terms of distribution and commercialization capabilities.

Bluebird Bio, Inc. 

Bluebird Bio and Rocket Pharmaceuticals compete in the gene therapy space, particularly for serious genetic diseases. While Rocket focuses primarily on adeno-associated virus (AAV) therapies for specific conditions like Fanconi anemia and other rare diseases, Bluebird has a broader pipeline that includes therapies for sickle cell disease and beta-thalassemia. Bluebird's experience with commercial launches might provide them a competitive advantage regarding market access and collaboration opportunities.

CRISPR Therapeutics AG 

CRISPR Therapeutics uses CRISPR gene-editing technology to develop therapies for various genetic diseases, representing a competitive threat to Rocket Pharmaceuticals. The use of CRISPR allows for precise genetic modifications, potentially enabling treatment options that differ from Rocket's AAV-based therapies. Given CRISPR's broad application across multiple diseases and its advanced research backing, it may hold a competitive advantage in the evolving landscape of gene therapy.

Editas Medicine, Inc. 

Editas Medicine specializes in genome editing utilizing CRISPR technology to develop therapies for genetically defined diseases. This directly competes with Rocket's AAV gene therapies, as both aim to address rare and severe genetic disorders. Editas's strong focus on specific high-impact genetic conditions may confer an advantage in the targeted patient population, particularly as they advance their pipeline towards the clinic.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics focuses on gene therapy and genome editing technologies, similar to Rocket Pharmaceuticals. Both companies target rare genetic disorders, but Sangamo has a broader approach that includes zinc finger nuclear proteins for gene editing. This allows Sangamo to pursue a diverse pipeline that addresses multiple diseases, potentially granting them a competitive edge in terms of therapeutic options and market reach.